9/24/2026
Psyence Biomedical invests $5M in ibogaine research
Psyence Biomedical's $5M investment aims to advance ibogaine program in the U.S.
Topic archive
mental health disorders
4 stories
9/23/2026
Clearmind expands U.S. patent portfolio with new applications
Patent applications cover novel combinations of LSD, ketamine, and ibogaine.
9/23/2026
NeuroThera expands U.S. patent portfolio with ibogaine
Collaboration with Clearmind Medicine enhances therapeutic potential for mental health and substance use disorders.
9/23/2026
NeuroThera expands U.S. patent portfolio with Clearmind
New patent applications cover LSD, ketamine, and ibogaine combinations for mental health.